GEN Exclusives

More »

GEN News Highlights

More »
Jul 10, 2007

Merz Pharmaceuticals Licenses Alzheimer’s Drug Technology from Tel Aviv University

  • A drug technology to treat Alzheimer's disease developed by a team of researchers at the George S. Wise Faculty of Life Sciences at Tel Aviv University (TAU) was licensed to Merz Pharmaceuticals.

    The technology developed at TAU was one of a portfolio of technologies that were selected to be funded by an $8.5M investment raised by Ramot, the university's tech transfer office, in 2003 from a group of U.S investors. 

    “Our goal is to offer novel therapeutic options to patients by developing innovative new drugs within our main area of expertise, the treatment of CNS disorders,” says Alexander Gebauer, head of global R&D at Merz Pharmaceuticals.

    The worldwide, exclusive rights include an upfront fee, milestone payments and royalties.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?